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ABSTRACT

Halogenated diarylacetylenes, e.g., diarylacetylenes having
at least one halo substituent in one aryl ring and an amine in
the opposing aryl ring, can inhibit the proliferation of
LSI 74T colon cancer cells through the inhibition of c-myc
and induction of the cyclin-dependent kinase inhibitor-I
(i.e., p21(Wifl/Cipl)). Such compounds are useful as anti
neoplastic agents.
12 Claims, 2 Drawing Sheets
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(I)

CROSS-REFERENCE TO RELATED
APPLICATION
This application claims the benefit of U.S. Provisional
Application No. 61/970,657 filed Mar. 26, 2014 the entire
disclosure of which is hereby incorporated by reference
herein.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH
This invention was made with govermnent support under
R21 CA139359 and ROI CAI 72379. The Govermnent has
certain rights in the invention.
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TECHNICAL FIELD
The present disclosure relates to halogenated diarylacetylenes for use as antineoplastic agents.

25

BACKGROUND
A family of fluorinated N,N-dialkylaminostilbene analogs
(FIDAS agents) that inhibit the expression of Wnt target
genes, such as c-myc, and repress colon cancer cell growth
in vitro and in vivo was recently described. See, e.g., J Med
Chem 2011: 54:1288-1297; ACS Chem Biol 2013: 8(4):796803; U.S. Pat. No. 8,664,276.
In addition, certain diarylacetylenes are known for certain
medicinal
uses.
See,
e.g.,
W02012149049;
W02012149048;
W02010092043;
W02009038759;
W02008073350; and W02001029011. Further, U.S. Pat.
No. 8,716,355 to Tsai discloses hydroxylated tolans and
related compounds in the treatment of cancer and Hadfield
et al disclose preparation and evaluation of diarylalkynes as
antitumor agents. Hadfield et al, Synthetic Communications
1998: 28(8):1421-1431. However, there is an ongoing need
for additional compounds that can be used to treat cancer
and other ailments.
SUMMARY OF THE DISCLOSURE
Advantages of the present disclosure include halogenated
diarylacetylenes and compositions having antineoplastic
activity and methods of inhibiting cancer cell growth and/or
treating cancer in a patient by administering one or more of
the halogenated diarylacetylenes or pharmaceutical compo
sitions thereof.
One aspect of the present disclosure is directed to halo
genated diarylacetylenes that are useful for killing hyper
proliferating cells such as cancer cells for the treatment of
human malignant and benign cancers, including without
limitation, colorectal cancer (CRC), breast cancer, lung
cancer, prostate cancer and liver cancer. In this aspect of the
disclosure, there are provided certain halogenated diary
lacetylenes having anti-neoplastic activity against cancerous
cells. The halogenated diarylacetylenes of the present dis
closure include compounds according to formula (I):
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or a pharmaceutically acceptable salt thereof, wherein
each ofX 1 throughX5 independently represents H, a lower
alkyl, or halo, provided that at least one ofX 1 throughX5 is
a halo; and each of Y 1 through Y 5 independently represents
H, a lower alkyl, or NR 1 R2, provided that at least one of Y 1
through Y 5 is NR 1 R2, wherein each of R 1 and R2 indepen
dently represents H, or a lower alkyl. In one aspect, of the
present disclosure the compound of formula (I) does not
include groups such as ester, hydroxyl, sulfonamide, amide,
urethane, and carboxyl groups.
The halogenated diarylacetylenes of formula (I) or phar
maceutically acceptable salts thereof can be included in a
pharmaceutical composition with a pharmaceutically
acceptable carrier.
Another aspect of the present disclosure is directed to
methods of treating cancer, e.g., inhibiting cancer cell
growth and/or inhibiting tumor growth in a mammal, such as
a human, or treating diseases associated with hyperproliferating cells. In one embodiment of this aspect of the
disclosure, an effective amount of one or more halogenated
diarylacetylenes, pharmaceutical salts and/or pharmaceuti
cal compositions thereof is administered to a patient in need
of treatment of cancer sufficient to treat/inhibit cancer cell
growth in the patient.
In an embodiment of this aspect of the disclosure, a
therapeutically effective amount of one or more halogenated
diarylacetylenes, pharmaceutical salts and/or pharmaceuti
cal compositions thereof is administered to a patient suffering from colorectal cancer. In another embodiment, a thera
peutically effective amount of one or more halogenated
diarylacetylenes, pharmaceutical salts and/or pharmaceuti
cal compositions thereof is administered to a patient suffering from liver cancer or prostate cancer.
Additional advantages of the present invention will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the invention is shown and described, simply
by way of illustration of the best mode contemplated of
carrying out the invention. As will be realized, the invention
is capable of other and different embodiments, and its
several details are capable of modifications in various obvi
ous respects, all without departing from the invention.
Accordingly, the drawings and description are to be regarded
as illustrative in nature, and not as restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
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Reference is made to the attached drawings, wherein
elements having the same reference numeral designations
represent similar elements throughout and wherein:
FIG. 1 is a schematic illustration of the synthesis of
halogenated
diarylacetylenes
2.
Reagents:
a,
HC CHC6H4 Y; 0.5% Pd(PPh3)4, 1% Cul, H20, 75° C., 1-2
h; b, a, HC CHC6H4NH2 ; 0.5% Pd(PPh3 )4, 1% Cul, H20,
75° C., 1-2 h followed by CH3 I, K2C03 , acetone, 5 h, 56°
C.
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FIG. 2 is a blot showing inhibition of c-myc and induction
of p21(Wifl/Cipl) by diarylacetylenes 2 in colon cancer
cells. LS174T cells were treated with 1 µM of each diary
lacetylenes 2 for 36 h. DMSO and 1 were used as control.
Cell lysates were analyzed by western blotting with �-tubulin as a loading control.
DETAILED DESCRIPTION OF THE
DISCLOSURE
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The present disclosure relates to halogenated diarylacety
lenes, their salts and their pharmaceutical compositions and
methods of inhibiting cancer cell growth and/or treating
cancer in a patient by administering one or more of the
halogenated diarylacetylenes, a pharmaceutical salt thereof,
or a pharmaceutical composition thereof. It was found that
halogenated diarylacetylenes having at least one, preferably
two, halo substituents in one aryl ring and an amine in the
opposing aryl ring, e.g., N-methylamino or N,N-dimethyl
amino, inhibit the proliferation of LSI 74T colon cancer cells
through the inhibition of c-myc and induction of the cyclin
dependent kinase inhibitor-I (i.e., p21(Wifl/Cipl)). Such
compounds and compositions are useful as antineoplastic
agents.
The halogenated diarylacetylenes of the present disclosure include at least one amine group, e.g., a primary,
secondary or tertiary amine, on the aryl ring. Such com
pounds are useful as antineoplastic agents and can be
represented by the following formula:
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or a pharmaceutically acceptable salt thereof. The sub
stituents ofX 1 throughX5 each independently represent H,
a lower alkyl, or halo, provided that at least one of X 1
throughX5 is a halo. A halo group means an F, Cl, Br, I, or
At group. Preferably substituentsX 1 through X5 include at
least two halo groups, e.g., an F and/or Cl. Each of Y1
through Y5 independently represents H, a lower alkyl, or
NR 1 R2, provided that at least one of Y1 through Y5 is
NR 1 R2, wherein each of R 1 and R2 independently represents
H, or a lower alkyl. In one aspect, of the present disclosure
the compound of formula (I) does not include groups such
as ester, hydroxyl, sulfonamide, amide, urethane, and car
boxyl groups.
The term "lower alkyl" includes saturated aliphatic
groups, including straight-chain alkyl groups, branchedchain alkyl groups, cycloalkyl (alicyclic) groups, alkyl sub
stituted cycloalkyl groups, and cycloalkyl substituted alkyl
groups having from one to about ten carbons (C 1 -C 1 0), e.g.,
from one to about six carbon atoms (C 1 -C6) in its backbone
structure. In one aspect of the present disclosure, the lower
alkyl groups specifically include methyl, ethyl, propyl, iso
propyl, n-butyl, etc.
Embodiments of the halogenated diarylacetylenes of the
present disclosure include wherein at least two ofX 1 through
X5 is are halo groups, e.g., whereinX 1 throughX5 is either
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro
groups, and wherein both R 1 and R2 are lower alkyl groups,

e.g., methyl, ethyl, or butyl groups. PreferablyX 1 and/orX5
are halo groups, e.g., the diarylacetylenes have one or two
halogen substituents at ortho-positions relative to the acetylenic linkage, andX2 throughX4 are H or a lower alkyl. In
some embodiments, the halogenated diarylacetylenes
include compounds, or a pharmaceutically acceptable salt
thereof, where Y3 is NR 1 R2, and Y1 , Y2, Y4, and Y5
independently represent H, a lower alkyl, or NR 1 R2 . In other
embodiments, Y3 is NR 1 R2, and Y i , Y2, Y4, and Y5 independently represent H or a lower alkyl, e.g. Y1 , Y2, Y4, and
Y5 represent H. In still further embodiments, at least one of
R i , or R2, is a lower alkyl.
In another embodiment of the present disclosure, the
halogenated diarylacetylenes include compounds according
to formula (II):
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or a pharmaceutically acceptable salt thereof, wherein Y3
is NR 1 R2, and R i , R2, X 1 throughX5 and are as defined for
the compounds of formula (I) including the various embodiments for formula (I). Preferably, at least one of R 1 , or R2,
is a lower alkyl and at least two ofX 1 throughX5 are either
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro
groups. In another embodiment, both R i , and R2, are lower
alkyl, e.g., methyl, and at least two of X 1 through X5 are
either: (i) a fluoro and chloro, (ii) both fluoro, (iii) both
chloro groups. In some embodiments,X 1 and/orX5 are halo
groups, e.g., either a fluoro or chloro group.
Pharmaceutical compositions of the present disclosure
include one or more of compounds according to formula (I)
or a pharmaceutically acceptable salt thereof and a pharma
ceutically acceptable carrier. Preferable, pharmaceutical
compositions of the present disclosure include one or more
of compounds according to formula (II) and a pharmaceutically acceptable carrier.
In one aspect of the present disclosure, the compounds of
formula (I) or (II), a pharmaceutically acceptable salt
thereof, or a pharmaceutically acceptable composition
thereof is used in the treatment of cancer. The method
comprises administering to a patient in need of such treat
ment an effective amount of one or more of the halogenated
diarylacetylenes, a pharmaceutical salt thereof, or a pharmaceutical composition thereof. Embodiments of the
method include wherein the cancer treated is selected from
the group consisting of colorectal cancer, breast cancer, lung
cancer, prostate cancer and liver cancer.
In the course of developing new agents for the treatment
of cancers, we identified a family of fluorinated N,N
dialkylaminostilbene analogs (FIDAS agents) that inhibit
the expression of Wnt target genes, such as c-myc, and
repress colon cancer cell growth in vitro and in vivo.
Recently, we found that (E)-4-(2',6'-difluorostyryl)-N,Ndimethylaniline (1) (FIG. 1) targeted exclusively the cata
lytic subunit of methionine S-adenosyltransferase-2 (MAT2). See Zhang et al. ACS Chem Biol 2013: 8(4):796-803.
MAT-2 serves as a source of S-adenosylmethionine (SAM)
in colorectal and liver cancers where MAT-2 is upregulated.
See

US 9,895,324 B2
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Cai et al. Hepatology 1996: 24:1090-1097; Chen et al.
Gastroenterology 2007: 133:207-218; Ito et al. Surg Today
2000: 30:706-710; and Liu et al. J Biol Chem 2011: 286:
17168-17180.
It is believed that neoplastic tissues make effective use of
SAM from this isoform of MAT to manage crucial epigen
etic modifications of histone proteins and thereby regulate
gene expression. Interference with this process would rep
resent a new approach for developing potential antineoplastic agents. It is believed that the compounds of the present
disclosure inhibit c-myc. In addition, the present compounds
would avoid the facile E/Z-isomerizations that afflict the
stilbenes and complicate pharmacodynamic and pharma
cokinetic studies.
The diarylacetylenes 2 (FIG. 1), e.g., compounds of
formula (II), are a preferred group of halogenated diary
lacetylenes. Prior reports of acetylenic compounds as anti
neoplastic agents include monoalkylacetylenes from aquatic
organisms and diarylacetylenic analogs of combrestatin. See
Dembitsky et al. Nat. Prod. Commun. 2006: 1:773-812 and
Hadfield et al. Synth. Commun. 1998: 28:1421-1431. The
latter compounds showed cytotoxic activity against a murine
leukemia cell line and one showed activity as an inhibitor of
tubulin polymerization. The Sonogashira coupling of 4-(N,
N-dimethylamino)phenylacetylene with various aryl iodides
provided access to the desired diarylacetylenes 2 (Table 1).
(Additional information about Sonogashira coupling can be
found in Bhattacharya et al. Sengupta, S. Tetrahedron Lett.
2004: 47:8733-8736 and Okura et al. J. Org. Chem. 1993:
58:4716-4721). Prior work from our laboratories established
that stilbenes with N-methylamino and N,N-dimethylamino
groups in a para-orientation relative to the central double
bond as well as 2,6-difluoro, 2-chloro-6-fluoro or 2,6-di
chloro halogenation patterns in the other aromatic ring were
the most potent analogs in the inhibition of LSI 74T cell
proliferation. See Zhang et al. J Med Chem 2011: 54:12881297.
Table 1 below provides IC50 values for the inhibition of
LSI 74T cell proliferation for certain halogenated diary
lacetylenes of the present disclosure and stilbene compound
1 as shown in FIG. 1.

sion and inducing the cell cycle inhibitor, p21(Wifl/Cipl).
See Zhang et al. J Med Chem 2011: 54:1288-1297. The
similarity of the diarylacetylenes to the stilbenes also
prompted an in silica modeling study of the binding of
(E)-4-(2',6'-difluorostyryl)-N,N-dimethylaniline (1) and
4((2,6-difluorophenyl)ethynyl)-N,N-dimethylaniline (2m).
It was believed that para-oriented amino-substituents, such
as the N-methylamino and N,N-dimethylamino groups,
were associated with potent MAT2A inhibition. Using an
artificially constructed homodimer of MAT2A, we observed
that 1 and 2m bound to the same active site and that
diarylacetylene 2m inhibited MAT2 at concentrations com
parable to that of the stilbene 1 (data not shown). Variability
in the MAT2A inhibition assay made the measurement of
c-myc inhibition a preferred analytical tool for assessing the
potency of diarylacetylenes.
We tested the effect of these diarylacetylenes 2 on the
proliferation of LSI 74T colon cancer cells. The expression
of c-myc and p21(Wifl/Cipl) were analyzed by western
blotting (FIG. 2). The most active diarylacetylenes 2 inhib
ited c-myc expression at 1 µM concentrations and as
expected for a c-myc inhibitor, induced p21(wifl/Cipl) at
the same time. Consistent with prior results in the stilbene
family, the diarylacetylenes 2 lacking halogen substituents
(e.g., 2c) or possessing only one fluorine substituent at a
meta- or para-position relative to the acetylenic linkage (e.g.,
2g) had very low potency (Table 1). Diarylacetylenes with
one or two halogen substituents at ortho-positions relative to
the acetylenic linkage (e.g., 2b, 2d, 2e, 2m and 2n) possessed
potencies as inhibitors of LSI 74T cell proliferation that
exceeded that of the related stilbene 1 with IC50 values less
than 50 nM (Table 1). Isomers of these diarylacetylenes
(e.g., 2f, 2g, 2j and 2k) with halogens in meta- or para
positions were significantly less active than the diarylacety
lenes with ortho-halogens. Once again, these results are in
consistent with the SAR findings in the stilbene family of
c-myc inhibitors. Zhang et al. J Med Chem 2011: 54:12881297. Finally, the N-methylation pattern in the diarylacety
lenes suggested that N-methyl and N,N-dimethylaniline
subunits led to equipotent inhibitors of c-myc (i.e., IC50 of
2bssIC50 of 2m) but the desmethyl analog was considerably
less active (IC50 of 2a=55±7.8 nm).
It was found that diarylacetylenes 2 have a dramatic effect
on the proliferation of LS174T colon cancer cells by altering
the expression of c-myc and thereby inducing p21(Wifl/
Cipl). These results are consistent with similar findings
using halogenated stilbenes and suggest that diarylacetylenes and stilbenes repress colon cancer proliferation
through similar mechanisms.
In an aspect of the present disclosure, the following
particular halogenated diarylacetylenes and their pharma
ceutical salts and pharmaceutical compositions can be used
to treat cancer, CRC: 4-((2,6-Difluorophenyl)ethynyl)ani
line (2a); 4-((2,6-Difluorophenyl)ethynyl)-N-methylaniline
(2b); N,N-Dimethyl-4-(phenylethynyl)aniline (2c); 4-((2Fluorophenyl)ethynyl)-N,N-dimethylaniline (2d); 4-((2Chlorophenyl)ethynyl)-N,N-dimethylaniline (2e); 4-((3Fluorophenyl)ethynyl)-N,N-dimethylaniline (2f); 4-((4Fluorophenyl)ethynyl)-N,N-dimethylaniline (2g); 4-((2,3Difluorophenyl)ethynyl)-N,N-dimethylaniline (2 h); 4-((2,
4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2i); 4-((3,
4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2j); 4-((3,
5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2k); 4-((2,
5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (21); 4-((2,
6-Difluorophenyl)ethynyl)-N,N-dimethylaniline
(2m),
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TABLE 1

Compound
2a
2b
2c
2d
2e
2f
2g
2h
2i
2j
2k
21
2m
2n
2o

Inhibition of 45
LS174T Cell
Proliferation
IC50 (nM)

X 1 X2
F
F
F

F
F
F
F
Cl
F
F
F
F
F
Cl

F
F
F
F

F
F
F

F
F

F
Cl
Cl

N(CH3)2
NH2
NHCH3
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2
N(CH3)2

59 ± 7.5
55 ± 7.8
23 ± 10.3
>3000
39 ± 6.0
31 ± 3.1
>3000
>3000
119 ± 4.6
56 ± 8.1
>3000
>3000
55 ± 6.0
23 ± 6.0
19 ± 5.0
52 ± 7.1

SAR studies were undertaken for those diarylacetylenes 2
that possessed fluorine or chlorine substituents in one aryl
ring and N-methylamino or N,N-dimethylamino in the other
aryl ring. We reported previously that stilbenes repressed
colon cancer cell proliferation by inhibiting c-myc expres-
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4-((2-Chloro-6-fluorophenyl)ethynyl )-N,N-dimethylaniline
(2n), and/or 4-((2,6-Dichlorophenyl)ethynyl)-N,N-dimeth
ylaniline (2o).
EXAMPLES
The following examples are intended to further illustrate
certain preferred embodiments of the invention and are not
limiting in nature. Those skilled in the art will recognize, or
be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and
procedures described herein.
Cell Proliferation Assay.
LSI 74T cells were grown in RPMI medium (Mediatech)
supplemented with 5% fetal bovine serum and 1% penicil
lin/streptomycin. For cell proliferation assays, 3xl04 cells/
well growing in 12-well plates were treated with DMSO or
inhibitors. The cell numbers and viability were analyzed by
Vi-Cell Cell Viability Analyzer after 4 days. The IC50 values
were calculated with GraphPad Prim 5.
Western Blotting.
Western blot was performed as described previously 1 . The
following antibodies were used: anti-c-myc (Epitomics,
1472-1), anti-p21(Wifl/Cipl) (Cell Si gnaling, 2947), anti�-tubulin (DSHB, E7).
Materials.
Chemicals were purchased from Si gma Aldrich or Fisher
Scientific or were synthesized according to literature proce
dures. Solvents were used from commercial vendors without
further purification unless otherwise noted. Nuclear mag
netic resonance spectra were determined on a Varian instru
ment ( 1 H, 400 MHz; 13 C, 100 Mz). High resolution elec
trospray ionization (ESI) mass spectra were recorded on a
LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, Mass., USA). The FT resolution was set at
100,000 (at 400 m/z). Samples were introduced through
direct infusion using a syringe pump with a flow rate of 5
µUmin. Purity of compounds was established by combustion analyses by Atlantic Microlabs, Inc., Norcross, Ga.
Compounds were chromatographed on preparative layer
Merck silica gel F254 unless otherwise indicated.
Synthesis of Diarylacetylenes.
A general procedure for the synthesis of diarylacetylenes
2 involved the addition of 2.0 mmol of arylacetylene to a
mixture of 2.1 mmol of an aryliodide, 3.0 mmol of diiso
proprylethylamine, 0.02 mmol of Pd(PPh3)4, and 0.02 mmol
of Cul in water (7 mL). The mixture was stirred for 1-2 h at
75 ° C. After cooling, the product was collected by filtration
or extracted using dichloromethane and purified by recrys
tallization and/or chromatography.
Characterization and Analytical Data Fordiarylacetylenes 2.
4-((2,6-Difluorophenyl)ethynyl)aniline (2a)
Purified by chromatography on silica gel using 1:2ethyl
acetate-hexane (Rf=0.43). Yield 65%, mp 104-105° C. 1 H
NMR (DMSO-d 6): Ii 7.46-7.39 (m, lH), 7.22 (d, 2H, 1=8.8
Hz), 7.20-7.16 (m, 2H), 6.58 (d, 2H, 1=8.8 Hz), 5.69 (s, 2H,
NH2). 13 C NMR (DMSO-d6): Ii 161.72 (dd, 11=248.9 Hz,
12=5.3 Hz, two C), 150.21, 132.77 (two C), 129.89 (t, 1=9.9
Hz), 113.60 (two C), 111.68 (dd, 11=18.2 Hz, 12=6.l Hz, two
C), 106.96, 101.96 (t, 1=19.8 Hz), 102.28 (d, 1=2.7 Hz),
73.11. HRMS (ESI) calcd for C 14H9F2N [MH+]: 230.07758.
Found: 230.07660. Anal. Calcd for C 14H9F2 N: C, 73.36; H,
3.96. Found: C, 73.10; H, 4.03.

4-((2,6-DifluorophenyI)ethyny1)-N-methylaniline
(2b)
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To a solution of 200 mg (0.87 mmol) of 2a in acetone (4
mL) was added successively 145 mg (1.04 mmol, 1.2 equiv)
of potassium carbonate and 161 mg (1.13 mmol, 1.3 equiv)
of iodomethane. The mixture was refluxed for 5 h. After
cooling, the product was diluted with water, extracted with
dichloromethane, dried over MgS04 and concentrated. The
product was purified by chromatography on silica gel using
1:5ethyl acetate-hexane (Rf=0.48) to afford 68 mg (32%) of
2b. Mp 69-70° C. 1 H NMR (CDCl3 ): Ii 7.40 (d, 2H, 1=8.8
Hz), 7.24-7.15 (m, lH), 6.92-6.87 (m, 2H), 6.53 (d, 2H,
1=8.8 Hz), 3.95 (br s, lH), 2.84 (s, 3H). 13 C NMR (CDCl3):
Ii 162.92 (dd, 11=251.2 Hz, 12=5.3 Hz, two C), 149.92,
133.35 (two C), 128.77 (t, 1=9.8 Hz), 112.08 (two C), 111.25
(dd, 1 1=19.0 Hz, 12=6.0 Hz, two C), 110.34, 103.39 (t,
1=19.7 Hz), 100.89 (t, 1=3.1 Hz), 74.16, 30.48. HRMS (ESI)
calcd for C 15 HuF2 N [MH+]: 244.09323. Found: 244.09241.
Anal. Calcd for C 15 HuF2N: C, 74.06; H, 4.56. Found: C,
73.89; H, 4.71.
N,N-Dimethyl-4-(phenylethynyl)aniline (2c)
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Purified by recrystallization from hexane. Yield 88%, mp
104-106° C. 1 H NMR (DMSO-d6): Ii 7.49-7.47 (m, 2H),
7.41-7.33 (m, SH), 6.71 (d, 2H, 1=9.2 Hz), 2.94 (s, 6H). 13C
NMR (DMSO-d 6): Ii 150.10, 132.38 (two C), 130.86 (two
C), 128.61 (two C), 127.83, 123.29, 111.84 (two C), 108.41,
90.90, 87.16, 39.66 (two C). HRMS (ESI) calcd for
C 1 6H 1 5N [MH+]: 222.12773. Found: 222.12713.
4-((2-Fluorophenyl)ethyny 1)-N,N-dimethylaniline
(2d)
Purified by recrystallization from hexane. Yield 62%, mp
94-96° C. 1 H NMR (DMSO-d 6): Ii 7.57-7.53 (m, lH),
7.43-7.34 (m, 3H), 7.31-7.22 (m, lH), 7.24-7.20 (m, lH),
6.71 (d, 2H, 1=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d 6):
ll 161.47 (d, 1=246.7 Hz), 150.32, 132.96, 132.46 (two C),
129.91 (d, 1=7.6 Hz), 124.64 (d, 1=3.8 Hz), 115.55 (d,
1=20.5 Hz), 111.81 (two C), 111.63 (d, 1=15.2 Hz), 107.83,
96.02 (d, 1=3.0 Hz), 80.38, 39.62 (two C). HRMS (ESI)
calcd for C 1 6H 14FN [MH+]: 240.11830. Found: 240.11726.
Anal. Calcd for C 1 6H 14FN: C, 80.31; H, 5.90. Found: C,
80.04; H, 6.03.
4-((2-Chlorophenyl)ethynyl)-N,N-dimethylaniline
(2e)
Purified by recrystallization from ethanol. Yield 56%, mp
108-110° C. 1 H NMR (DMSO-d 6): Ii 7.60-7.54 (m, 2H),
7.38-7.34 (m, 4H), 6.73 (d, 2H, 1=8.8 Hz), 2.96 (s, 6H). 13C
NMR (DMSO-d 6): ll 150.40, 134.00, 133.33, 132.76, 132.55
(two C), 129.28, 127.27, 122.96, 111.85 (two C), 107.80,
96.27, 84.08, 39.67 (two C). HRMS (ESI) calcd for
C 1 6H 14CIN [MH+]: 256.08875. Found: 256.08805.
4-((3-Fluorophenyl)ethyny 1)-N,N-dimethylaniline
(2f)
Purified by recrystallization from hexane. Yield 87%, mp
99-100° C. 1 H NMR (DMSO-d 6): Ii 7.45-7.31 (m, SH),
7.22-7.17 (m, lH), 6.71 (d, 2H, 1=9.2 Hz), 2.95 (s, 6H). 13C
NMR (DMSO-d 6): ll 161.90 (d, 1=242.8 Hz), 150.30, 132.55
(two C), 130.66 (d, 1=8.4 Hz), 127.19 (d, 1=2.2 Hz), 125.32
(d, 1=9.9 Hz), 117.31 (d, 1=22.7 Hz), 115.02 (d, 1=21.3 Hz),
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111.81 (two C), 107.79, 92.09, 86.07 (d, 1=3.0 Hz), 39.64
(two C). HRMS (ESI) calcd for C 16H 14FN [MH+]:
240.11830. Found: 240.11750. Anal. Calcd for C 16H 14FN:
C, 80.31; H, 5.90. Found: C, 80.03; H, 6.10.
4-((4-Fluorophenyl)ethyny1)-N,N-dimethy!aniline
(2g)
Purified by recrystallization from methanol. Yield 92%,
mp 132-134 ° C. 1H NMR (DMSO-d6): ll 7.54-7.51 (m, 2H),
7.35 (d, 2H, 1=8.8 Hz),3 7.24-7.20 (m, 2H), 6.70 (d, 2H, 1=9.2
Hz), 2.94 (s, 6H). 1 C NMR (DMSO-d6): Ii 161.47 (d,
1=245.l Hz), 150.12, 133.07 (d, 1=8.4 Hz, two C), 132.35
(two C), 119.74 (d, 1=3.8 Hz), 115.80 (d, 1=22.1 Hz, two C),
111.83 (two C), 108.26, 90.56, 86.07, 39.65 (two C). HRMS
(ESI) calcd for C 16H 14FN [MH+]: 240.11830. Found:
240.11752.
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4-((2,3-Difluorophenyl)ethynyl)-N,N-dimethylani
line (2 h)
Purified by recrystallization from methanol. Yield 65%,
mp 104-106 ° C. 1H NMR (DMSO-d6): ll 7.46-7.37 (m, 4H),
3
7.24-7.19 (m, lH), 6.72 (d, 2H, 1=8.0 Hz), 2.91 (s, 6H). 1 C
=
=
NMR (DMSO-d6): ll 149.78 (dd, 11 244.4 Hz, 12 11.4 Hz),
149.37 (dd, 11=247.1 Hz, 12=13.8 Hz), 132.62 (two C),
128.15 (d, 1=4.0 Hz), 125.14 (d, 1=4.6 Hz), 125.06 (d, 1=4.6
Hz), 117.21 (d, 1=16.7 Hz), 113.87 (d, 1=11.4 Hz), 111.80
(two C), 107.20, 97.54 (d, 1=3.8 Hz), 79.23 (d, 1=4.6 Hz),
39.60 (two C). HRMS (ESI) calcd for C 16H 13F2 N [MH+]:
258.10888. Found: 258.10818. Anal. Calcd for C 16H 13F2 N:
C, 74.69; H, 5.09. Found: C, 74.43; H, 5.22.

20

25

30

4-((2,4-Difluorophenyl)ethynyl)-N,N-dimethylani
line (2i)
Purified by recrystallization from methanol. Yield 82%,
mp 116-118 ° C. 1H NMR (DMSO-d6): ll 7.65-7.59 (m, lH),
7.40-7.34 (m, 3H), 7.15-7.11
(m, lH), 6.71 (d, 2H, 1=9.2
3
Hz), 2.95 (s, 6H). 1 C NMR (DMSO-d6): Ii 161.79 (dd,
1 1=249.3 Hz, 12=12.5 Hz), 150.35, 161.63 (dd, 1 1=247.8 Hz,
12=11.8 Hz), 134.11 (dd, 1 1=9.8 Hz, 12=2.3 Hz), 132.44 (two
C), 112.15 (dd, 11=22.0 Hz, 12=3.8 Hz), 111.81 (two C),
108.31 (dd, 11=15.6 Hz, 12=4.2 Hz), 107.68, 104.50 (t,
1=25.8 Hz), 95.75, 79.35, 39.63 (two C). HRMS (ESI) calcd
for C 16H 13F2 N [MH+]: 258.10888. Found: 258.10806.
Anal. Calcd for C 16H 13 F2 N: C, 74.69; H, 5.09. Found: C,
74.61; H, 5.23.
4-((3,4-Difluorophenyl)ethynyl)-N,N-dimethylani
line (2j)
Purified by recrystallization from methanol. Yield 93%,
mp 100-101 ° C. 1H NMR (DMSO-d6): ll 7.60-7.55 (m, lH),
7.48-7.41 (m, lH), 37.37-7.32 (m, 3H), 6.71 (d, 2H, 1=9.2
Hz), 2.95 (s, 6H). 1 C NMR (DMSO-d6): Ii 150.29, 149.21
(dd, 1 1=249.0 Hz, 12=14.5 Hz, two C), 132.49 (two C),
128.26 (dd, 1 1=6.4 Hz, 12=3.4 Hz), 128.68 (dd, 11=8.0 Hz,
12=4.2 Hz), 119.76 (d, 1=18.2 Hz), 118.00 (d, 1=16.7 Hz),
111.80 (two C), 107.69, 91.58, 85.21, 39.62 (two C). HRMS
(ESI) calcd for C 16H 13 F2 N [MH+]: 258.10888. Found:
258.10787. Anal. Calcd for C 16H 13F2 N: C, 74.69; H, 5.09.
Found: C, 74.80; H, 5.11.
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4-((3,5-Difluorophenyl)ethynyl)-N,N-dimethylani
line (2k)
Purified by recrystallization from methanol. Yield 84%,
mp 72-74 ° C. 1H NMR (DMSO-d6): Ii 7.37 (d, 2H, 1=8.8

65

Hz), 7.28-7.19 (m, 3H), 6.71 (d, 2H, 1=9.2 Hz), 2.96 (s, 6H).
13
C NMR (DMSO-d6): ll 162.27 (dd, \ =245.1 Hz, 12=14.4
Hz, two C), 150.47, 132.70 (two C), 126.29 (t, 1=12.1 Hz),
113.95 (dd, 11=19.0 Hz, 12=7.6 Hz, two C), 111.78 (two C),
107.22, 103.94 (t, 1=25.8 Hz), 93.42, 85.33 (t, 1=3.8 Hz),
39.60 (two C). HRMS (ESI) calcd for C 16H 13F2 N [MH+]:
258.10888. Found: 258.10787. Anal. Calcd for C 16H 13F2 N:
C, 74.69; H, 5.09. Found: C, 74.43; H, 5.20.
4-((2,5-Difluorophenyl)ethynyl)-N,N-dimethylani
line (21)
Purified by recrystallization from methanol. Yield 79%,
mp 106-107° C. 1H NMR (DMSO-d6): ll 7.45-7.41 (m, lH),
7.39-7.32 (m, 3H), 7.28-7.22
(m, lH), 6.72 (d, 2H, 1=9.2
3
Hz), 2.96 (s, 6H). 1 C NMR (DMSO-d6): Ii 157.89 (dd,
\=243.6 Hz, 12=2.3 Hz), 157.80 (dd, \=239.9 Hz, 12=2.3
Hz), 150.52, 132.62 (two C), 118.82 (d, 1=25.8 Hz), 117.04
(dd, 1 1=24.3 Hz, 12=9.l Hz), 116.53 (dd, 1 1=24.3 Hz, 12=8.3
Hz), 113.01 (dd, 11=18.2 Hz, 12=10.7 Hz), 111.80 (two C),
107.23, 97.22 (d, 1=3.8 Hz), 79.61, 39.61 (two C). HRMS
(ESI) calcd for C 16H 13F2 N [MH+]: 258.10888. Found:
258.10812. Anal. Calcd for C 16H 13F2 N: C, 74.69; H, 5.09.
Found: C, 74.56; H, 5.21.
4-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylani
line (2m)
Purified by recrystallization from hexane. Yield 59%, mp
98-100 ° C. 1H NMR (DMSO-d6): ll 7.49-7.41 (m, lH), 7.37
7.23-7.18 (m, 2H), 6.72 (d, 2H, 1=8.8 Hz),
(d, 2H, 1=8.8 Hz),
3
2.97 (s, 6H). 1 C NMR (DMSO-d6): ll 161.75 (dd, 11=248.9
Hz, 12=5.3 Hz, two C), 150.58, 132.59 (two C), 130.12 (t,
1=10.3 Hz), 111.76 (dd, 11=17.9 Hz, 12=4.3 Hz, two C),
111.82 (two C), 107.21, 101.83 (t, 1=19.8 Hz), 100.88 (t,
1=3.l Hz), 73.83, 39.64 (two C). HRMS (ESI) calcd for
C 16H 13F2 N [MH+]: 258.10888. Found: 258.10801. Anal.
Calcd for C 16H 13F2 N: C, 74.69; H, 5.09. Found: C, 74.47;
H, 5.24.
4-((2-Chloro-6-fluorophenyl)ethynyl)-N,N-dimeth
ylaniline (2n)
Purified by chromatography on silica gel using 1:5ethyl
acetate-hexane (Rf=0.74). Yield 53%, mp 86-88 ° C. 1H
(m, SH), 6.73 (d, 2H, 1=8.8
NMR (DMSO-d6): Ii 7.45-7.30
3
Hz), 2.97 (s, 6H). 1 C NMR (DMSO-d6): Ii 161.89 (d,
1=249.7 Hz), 150.62, 135.11 (d, 1=3.0 Hz), 132.64 (two C),
129.90 (d, 1=9.1 Hz), 125.37 (d, 1=3.0 Hz), 114.37 (d,
1=21.2 Hz), 112.37 (d, 1=18.2 Hz), 111.84 (two C), 107.24,
101.55 (d, 1=3.8 Hz), 77.59, 39.64 (two C). HRMS (ESI)
calcd for C 16H 13 CIFN [MH+]: 274.07933. Found:
274.07858. Anal. Calcd for C 16H 13 CIFN: C, 70.20; H, 4.79.
Found: C, 70.43; H, 4.76.
4-((2,6-Dichlorophenyl)ethynyI )-N,N-dimethy!ani
line (2o)
Purified by recrystallization from ethanol. Yield 54%, mp
96-98° C. 1H NMR (DMSO-d6): Ii 7.52 (d, 2H, 1=8.0 Hz),
3
7.37-7.29 (m, 3H), 6.70 (d, 2H, 1=9.2 Hz), 2.93 (s, 6H). 1 C
NMR (DMSO-d6): Ii 150.66, 135.26, 133.31, 132.67 (two
C), 129.40, 127.97 (two C), 122.79, 111.82 (two C), 107.22,
101.91, 81.62, 39.61 (two C). HRMS (ESI) calcd for
C 16H 13 Cl2 N [MH+]: 290.04978. Found: 290.04888. Anal.
Calcd for C 16H 13 Cl2 N: C, 66.22; H, 4.52. Found: C, 66.06;
H, 4.70.
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Only the preferred embodiment of the present invention
and examples of its versatility are shown and described in
the present disclosure. It is to be understood that the present
invention is capable of use in various other combinations
and environments and is capable ofchanges or modifications
within the scope of the inventive concept as expressed
herein. Thus, for example, those skilled in the art will
recognize, or be able to ascertain, using no more than routine
experimentation, numerous equivalents to the specific sub
stances, procedures and arrangements described herein.
Such equivalents are considered to be within the scope of
this invention, and are covered by the following claims.
What is claimed is:
1. A method of treating colorectal cancer, the method
comprising administering to a patient in need of such
treatment an effective amount of a compound according to
the following formula:
(I)
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or a pharmaceutically acceptable salt thereof, wherein
each of X 1 through X5 independently represents H, a
lower alkyl, or halo, provided that at least one of X 1
through X5 is a halo; and each of Y1 through Y5
independently represents H, a lower alkyl, or NR1 R2 ,
provided that at least one ofY1 through Y5 is NR1 R2 ,
wherein each ofR1 and R2 independently represents H,
or a lower alkyl, provided that at least one of R1 or R2
is a lower alkyl.
2. The method of claim 1, wherein at least two of X 1
through X5 are halo groups.
3. The method of claim 2, wherein X 1 through X5 are
either (i) a fluoro and chloro, (ii) both fluoro, or (iii) both
chloro groups.
4. The method of claim 1, wherein both R1 and R2 are
lower alkyl groups.

5. The method ofclaim 4, wherein either X 1 or X5 or both
X 1 and X5 are halo groups and X2 through X4 are H or a
lower alkyl.
6. The method of claim 1, wherein X 1 and/or X5 are halo
groups, X2 through X4 are H or a lower alkyl, Y3 is NR1 R2 ,
and Y1 , Y2, Y4, and Y5 independently represent H or a lower
alkyl.
7. The method ofclaim 1, wherein X 1 and/or X5 are fluoro
and/or chloro and at least one of R1 or R2 is a lower alkyl.
8. A pharmaceutical composition comprising a therapeu
tically effective amount of a compound according to the
following formula:
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or a pharmaceutically acceptable salt thereof, wherein
each of X 1 through X5 independently represents H, a
lower alkyl, a fluoro or a chloro, provided that at least
one ofX 1 through X5 is a fluoro or chloro; and each of
Y1 through Y5 independently represents H, a lower
alkyl, or NR1 R2 , provided that at least one of Y 1
through Y5 is NR1 R2 , wherein each of R1 and R2
independently represents H, or a lower alkyl, provided
that at least one of R1 or R2 is a lower alkyl; and a
pharmaceutically acceptable carrier, wherein the phar
maceutical composition is acceptable to be adminis
tered to a mammal.
9. The pharmaceutical composition of claim 8, wherein at
least two ofX 1 through X5 are fluoro, or chloro groups and
the remaining X 1 through X5 are H.
10. The pharmaceutical composition of claim 8, wherein
X 1 and X5 are either (i) a fluoro and chloro, (ii) both fluoro,
(iii) both chloro groups.
11. The pharmaceutical composition of claim 8, wherein
at least one of R1 , or R2 , is a lower alkyl.
12. The pharmaceutical composition of claim 11, wherein
the lower alkyl is methyl or ethyl.

* * * * *

